Medication classes
IL-12/23 inhibitor articles covering treatments such as ustekinumab, including safety, effectiveness, approvals, and access. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 3 of 4 · 157 articles
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
The report suggests tofacitinib (a JAK inhibitor), alone or combined with ustekinumab, could be an effective option for some infants with treatment-refractory IOIBD — a population with few evidence-based alternatives. If...
Perianal fistulizing Crohn's disease is difficult to treat and many patients have failed anti-TNF therapy. Evidence that ustekinumab achieves high clinical fistula response and remission rates in a real-world multicenter...
Perianal fistulas are a serious complication of Crohn’s disease with limited high-quality trial evidence. This randomized trial suggests ustekinumab may increase the chance of combined clinical and MRI remission at 12...
This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...
This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...
People with Crohn's disease and their clinicians often ask how different treatments affect cancer risk. This large nationwide study provides real-world estimates of absolute excess cancer cases by treatment group, which...
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
An FDA label update for PYZCHIVA adds/clarifies that this ustekinumab product is indicated for Crohn's disease and ulcerative colitis and reiterates safety monitoring steps (for infections and TB) that matter to people...
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...
People with ulcerative colitis who have had colectomy can rarely develop inflammation of the small intestine and high-output stomas that are hard to control.
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from DailyMed.
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
This trial directly tests common clinical strategies for managing loss of response to ustekinumab in Crohn’s disease. The findings may change whether doctors routinely escalate to 4-weekly dosing after an IV reinduction,...
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Ustekinumab. Open the original article for the full details.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from jnj.com.
Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from msn.com.
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
An interchangeable biosimilar to ustekinumab could expand access and lower costs for people with Crohn’s disease and ulcerative colitis who use Stelara. Pharmacists may be able to substitute the biosimilar for the...
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
Formulary listings for Yesintek (ustekinumab biosimilar) could make an established IBD treatment more affordable and accessible for people with Crohn’s disease or ulcerative colitis. Wider payer coverage may affect which...
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...
A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other...
A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...
A CHMP positive opinion means guselkumab (Tremfya) could become an approved treatment option for adults with moderately to severely active Crohn’s disease in the EU, offering both IV and SC induction routes. This could...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
A newly FDA-approved option (Tremfya/guselkumab) may offer more flexible dosing that could affect how people with moderate-to-severe Crohn’s start biologic treatment.
This approval adds an FDA-cleared IL-23 biologic (Tremfya) as a treatment option for adults with moderately to severely active Crohn’s disease, which may affect treatment choices. It also comes as multiple biosimilars to...
A new FDA approval expands treatment options for adults with moderately to severely active Crohn’s disease, including a fully subcutaneous IL-23 inhibitor regimen that could offer more flexibility. The approval was based...
An FDA approval means a new biologic option (guselkumab/Tremfya) is available for adults with moderately to severely active Crohn’s disease and may change prescribing choices. The approval highlights a dosing flexibility...
A newly FDA‑approved IL‑23 drug for Crohn’s may increase treatment options for people with IBD, including an IV and a subcutaneous formulation. The approval could affect switching decisions for patients not responding to...
A newly FDA-approved biologic (guselkumab/Tremfya) offers another treatment option for adults with moderate to severe Crohn’s disease, including both IV and SC induction choices. This could matter for patients who have...
Cure8 found this source from drugstorenews.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
